Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer.

Cancer research and treatment（2023）

引用 2|浏览27

暂无评分

摘要

Osimertinib demonstrated its clinical effectiveness and survival benefit for EGFR T790M mutation-positive in Korean patients with no new safety signals.

查看译文

关键词

EGFR T790M,Non–small cell lung cancer,Osimertinib,Real-world efficacy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要